Landmark partnership announced for development of COVID-19 vaccine
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.
The partnership is to begin immediately with the final terms being agreed in the coming weeks. This will allow for rapid vaccination around the world if the COVID-19 vaccine candidate proves to be effective. The vaccine candidate was developed by the University’s Jenner Institute who began trials in humans last week jointly with the University’s Oxford Vaccine Group.
It is the first such partnership to be formed since the Government launched its dedicated Vaccines Taskforce to help find, test and deliver a new coronavirus vaccine just two weeks ago. It also comes alongside £20 million Government funding for Oxford University’s vaccine research and support for the institution’s clinical trials.
Under the new agreement, as well as providing UK access as early as possible if the vaccine candidate is successful, AstraZeneca will work with global partners on the international distribution of the vaccine, particularly working to make it available and accessible for low and medium income countries.
Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered. Oxford University and its spin-out company Vaccitech, who jointly have the rights to the platform technology used to develop the vaccine candidate, will receive no royalties from the vaccine during the pandemic. Any royalties the University subsequently receives from the vaccine will be reinvested directly back into medical research, including a new Pandemic Preparedness and Vaccine Research Centre. The centre is being developed in collaboration with AstraZeneca.
Professor Sir John Bell, Regius Professor of Medicine at Oxford University, said: “Our partnership with AstraZeneca will be a major force in the struggle against pandemics for many years to come. We believe that together we will be in a strong position to start immunising against coronavirus once we have an effective approved vaccine. Sadly, the risk of new pandemics will always be with us and the new research centre will enhance the world’s preparedness and our speed of reaction the next time we face such a challenge.”
The Vice-Chancellor of Oxford University, Professor Louise Richardson said: “Like my colleagues all across Oxford, I am deeply proud of the work of our extraordinarily talented team of academics in the Jenner Institute and the Oxford Vaccine Group. They represent the best tradition of research, teaching and contributing to the world around us, that has been the driving mission of the University of Oxford for centuries. Like people all across the country, we are wishing them success in developing an effective vaccine. If they are successful, our partnership with Astra Zeneca will ensure that the British people and people across the world, especially in low and middle income countries, will be protected from this terrible virus as quickly as possible.”
Business Secretary Alok Sharma said: “This collaboration between Oxford University and AstraZeneca is a vital step that could help rapidly advance the manufacture of a coronavirus vaccine. It will also ensure that should the vaccine being developed by Oxford University’s Jenner Institute work, it will be available as early as possible, helping to protect thousands of lives from this disease.”
Health Secretary Matt Hancock said: “Across government, we are working night and day to stop the spread of coronavirus and protect our NHS. But in the long run, a vaccine remains our best hope of defeating this virus for good. So I am determined to do everything in my power to develop an effective vaccine and get it to the people of the UK as soon as possible. I want the UK to lead the world in developing a coronavirus vaccine - and I will back our scientists to the hilt in doing so.”
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “As COVID-19 continues its grip on the world, the need for a vaccine to defeat the virus is urgent. This collaboration brings together University of Oxford’s world-class expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities. Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation.”
Bill Enright, CEO of Vaccitech, said: “We are delighted to facilitate this extensive collaboration in support of the development of the vaccine candidate in order to make it available as quickly as possible. We believe this vaccine candidate provides significant validation for our ChAdOx platform, which is one of the few to have already induced neutralising antibodies against coronavirus spike proteins in human studies for MERS. We are committed to doing all we can to support our scientific founders at the Jenner Institute in order to overcome this unprecedented global crisis."